Advanced adenocarcinoma of the lung: Comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation

Radiology

Volumn 275, Issue 1, 2015, Pages 272-279

  Choi, Chang Min ^a,b   Kim, Mi Young ^c   Hwang, Hye Jeon ^e   Lee, Jung Bok ^d   Kim, Woo Sung ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Department of Oncology ^*  (South Korea)

^c Research Institute of Radiology   (South Korea)

^d University of Ulsan   (South Korea)

^e Hallym University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; IOPROMIDE; CONTRAST MEDIUM; IOHEXOL; PROTEIN TYROSINE KINASE;

ADULT; ALK GENE; ARTICLE; BONE METASTASIS; CANCER STAGING; COMPARATIVE STUDY; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EGFR GENE; FEMALE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; LUNG ADENOCARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PERICARDIAL DISEASE; PERICARDIAL METASTASIS; PLEURA METASTASIS; PRIORITY JOURNAL; RADIOLOGIST; RETROSPECTIVE STUDY; TUMOR VOLUME; ADENOCARCINOMA; AGED; ANALOGS AND DERIVATIVES; BRONCHOSCOPY; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC USE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; LUNG TUMOR; LYMPHOSCINTIGRAPHY; MIDDLE AGED; MUTATION; NEEDLE BIOPSY; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROCEDURES; RADIOGRAPHY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BRONCHOSCOPY; CARCINOMA, NON-SMALL-CELL LUNG; CONTRAST MEDIA; FEMALE; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; IOHEXOL; LUNG NEOPLASMS; LYMPHOSCINTIGRAPHY; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84926472126     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14140848     Document Type: Article

References (21)

1. Kerr KM. Pulmonary adenocarcinomas: classification and reporting. Histopathology 2009;54(1):12-27.
2. Travis WD; IASLC Staging Committee. Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM classification based on recommendations of the IASLC Staging Committee. Histopathology 2009;54(1):3-11.
3. Horn L, Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol 2009;27(26):4232-4235.
4. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmallcell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-2139.
5. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304(5676):1497-1500.
6. Aoki T, Hanamiya M, Uramoto H, Hisaoka M, Yamashita Y, Korogi Y. Adenocarcinomas with predominant ground-glass opacity: correlation of morphology and molecular biomarkers. Radiology 2012;264(2):590-596.
7. Gevaert O, Xu J, Hoang CD, et al. Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data-methods and preliminary results. Radiology 2012;264(2):387-396.
8. Lee HJ, Kim YT, Kang CH, et al. Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. Radiology 2013;268(1):254-264.
9. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947-957.
10. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448(7153):561-566.
11. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368(25):2385-2394.
12. Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1, 000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC) [abstr]. J Clin Oncol 2011;29(Suppl): abstract 8085.
13. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010;16(22):5581-5590.
14. Paik JH, Choi CM, Kim H, et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 2012;76(3):403-409.
15. Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010;9:188.
16. Choi CM, Kim MY, Lee JC, Kim HJ. Advanced lung adenocarcinoma harboring a mutation of the epidermal growth factor receptor: CT findings after tyrosine kinase inhibitor therapy. Radiology 2014;270(2):574-582.
17. Choi CM. Overview of ALK and ROS1 Rearranged Lung Cancer. Tuberc Respir Dis (Seoul) 2013;75(6):236-237.
18. Zerhouni EA, Stitik FP, Siegelman SS, et al. CT of the pulmonary nodule: a cooperative study. Radiology 1986;160(2):319-327.
19. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111(6):1710-1717.
20. Yeh ED, Jacene HA, Bellon JR, et al. What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach. RadioGraphics 2013;33(7):2003-2017.
21. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-1703.